Sign in
Taking people in GermanyNo phase

Tests a coronary sinus reducer device for hard-to-treat chest pain

Tests a heart device plus usual medicines in adults with refractory microvascular angina.

Key facts

Who runs it
Johannes Gutenberg University Mainz
Where
Mainz, GermanySee the site
Trial code
Registry title
COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina
Status
Recruiting
People taking part
144 people, planned
Started
1 Apr 2021
Expected to end
20 Oct 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Coronary sinus reducer
  • Optimal medical therapy
Record updated
28 September 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 85 with angina from disease of the small heart vessels that continues despite medicines. It tests a small device placed in the heart's coronary sinus (a vein that drains the heart) against medicines alone.

Age
18 to 85 years
Sex
All sexes can join, but women who could still become pregnant cannot (see exclusions).
Disease stage
Long-lasting coronary disease with severe angina (CCS class III-IV) despite guideline-directed medicines. Tests must show reversible ischemia (reduced blood flow that can recover) and small-vessel disease: IMR >25 and/or CFR <2.0 with FFR >0.8.
Earlier treatment
Angina must continue despite guideline-directed medical therapy. No heart attack or similar event (acute coronary syndrome) in the last 3 months, and no stent or bypass surgery in the last 6 months.
Biomarker or test result
Invasive tests must show small-vessel disease: index of microvascular resistance (IMR) >25 and/or coronary flow reserve (CFR) <2.0 with fractional flow reserve (FFR) >0.8.

Main reasons for not taking part

  • Decompensated heart failure or a hospital stay for heart failure in the last 3 months
  • Left ventricular ejection fraction <30%
  • Unusual coronary sinus shape, or coronary sinus diameter above 13mm or below 9.5mm
  • Chronic kidney failure (serum creatinine >2mg/dL (177 µmol/L)) or long-term hemodialysis
  • Women who could still become pregnant

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age ≥ 18 and ≤85 years
  • Chronic coronary syndrome (including patients with anginal equivalents) refractory angina CCS class III-IV despite guideline-directed medical therapy
  • Evidence of reversible ischemia on non-invasive testing
  • Evidence of microvascular disease as diagnosed invasively by at least one of the following:; index of microvascular resistances (IMR) >25 and/or; coronary flow reserve (CFR) <2.0) with fractional flow reserve (FFR)>0.8
  • Willingness to participate and ability to understand, read and sign the informed consent document before enrollment in the trial

Who cannot take part

  • Recent (within 6 months) revascularization by percutaneous coronary intervention (PCI, stent) or coronary artery by-pass surgery (CABG)
  • Known severe reaction to required procedural medications
  • Contraindication to dual antiplatelet therapy
  • Recent (within 3 months) acute coronary syndrome
  • Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months
  • Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory volume in one second that is less than 55 percent of the predicted value
  • Severe valvular heart disease
  • Known allergy to stainless steel or nickel
  • Left ventricular ejection fraction of <30%
  • Chronic renal failure (serum creatinine >2mg/dL), and/or on chronic hemodialysis
  • Subjects presenting at least one of the following criteria will not be enrolled in the trial
  • Recent (within 30 days) unsuccessful PCI
  • Mean right atrial pressure >15mmHg
  • Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left superior vena cava [SVC]) as demonstrated by angiogram
  • CS diameter at the site of planned Reducer implantation greater than 13mm or less than 9.5mm as measured by angiogram
  • A pacemaker electrode in the coronary sinus
  • Tricuspid valve replacement or repair
  • Moribund, or with comorbidities limiting life expectancy to less than one year
  • Need for Magnetic Resonance Imaging (MRI) within 8 weeks after reducer implantation
  • Female of childbearing potential (last menstruation within the last 12 months or who did not undergo tubal ligation, ovariectomy or hysterectomy)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in Germany

  • Center of Cardiology, Cardiology I, university hospital MainzMainz, GermanyContact: Tommaso Gori, Prof Dr, PhDTaking people

About the trial

What the trial wants to find out

Patients with refractory microvascular angina fulfilling the predefined inclusion and exclusion criteria will be enrolled in this randomized trial. The primary objective is to investigate whether the proportion of patients reporting an improvement in Canadian Cardiovascular Society (CCS) angina class (≥2 classes) is different at six months after implantation of a Coronary Sinus Reducer followed by optimal medical therapy (OMT) compared to OMT alone.

The 2 groups in the trial

  • Optimal medical therapyExisting treatment, for comparison

    Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines. Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)\<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina.

  • Coronary sinus reducerTreatment being tested

    The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicentric Randomized Open Label Controlled Superiority Trial to Evaluate the Effectiveness of a Therapy With a Coronary Sinus Reducer as Compared to Guideline-directed Medical Therapy in Patients With Refractory Microvascular Angina
Plain-language title
Tests a coronary sinus reducer device for hard-to-treat chest painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04606459, who can take part
Record updated
28 September 2023